Multistage adaptive biomarker-directed targeted design for randomized clinical trials

Contemporary Clinical Trials

Volumn 42, Issue , 2015, Pages 119-131

  Gao, Zhong ^a,c   Roy, Anindya ^a   Tan, Ming ^b  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Biomarker; Multistage adaptive design; Targeted clinical trial

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CLINICAL RESEARCH; CONTROLLED STUDY; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MULTISTAGE ADAPTIVE DESIGN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; STUDY DESIGN; BIOASSAY; ORGANIZATION AND MANAGEMENT; PERSONALIZED MEDICINE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

BIOMARKERS; DATA INTERPRETATION, STATISTICAL; EFFICIENCY, ORGANIZATIONAL; ENDPOINT DETERMINATION; HUMANS; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY;

EID: 84927154535     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.03.001     Document Type: Article

References (19)

1. Simon R., Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004, 10:6759-6763.
2. Maitournam A., Simon R. On the efficiency of targeted clinical trials. Stat Med 2005, 24:329-339.
3. Freidlin B., McShane L.M., Korn E.L. Randomized clinical trials with biomarkers: design issues 2010, 102(3):152-160.
4. Zhou X., Liu S., Kim E.S., Herbst R.S., Lee J.J. Bayesian adaptive design for targeted therapy development in lung cancer - a step toward, personalized medicine 2008, 5:181-193.
5. Lee J., Gu X., Liu S. Bayesian adaptive randomization designs for targeted agent development 2010, 7:584-596.
6. Wang S.J., Hung H.M.J., O'Neill R.T. Adaptive patient enrichment designs in therapeutic trials. Biom J 2009, 51(2):358-374.
7. Tang L., Zhou X.H. A general framework of marker design with optimal allocation to assess clinical utility. Stat Med 2013, 32:620-630.
8. Jennison C., Turnbull B.W. Group sequential methods with applications to clinical trials 2000, Chapman & Hall/CRC, New York, New York.
9. Chow S.C., Chang M., Pong A. Statistical consideration of adaptive methods in clinical development. J Pharm Stat 2005, 15:575-591.
10. Freidlin B., Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005, 11(21):7872-7878.
11. Jiang W., Freidlin B., Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007, 99:1036-1043.
12. Freidlin B., Jiang W., Simon R. The cross-validated adaptive signature design. Clin Cancer Res 2010, 16(2):691-698.
13. Pocock S.J. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977, 64:191-199.
14. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 1979, 35:549-556.
15. Spiegelhalter D.J., Freedman L.S., Blackburn P.R. Monitoring clinical trials: conditional or predictive power?. Control Clin Trials 1986, 7:8-17.
16. Proschan M.A., Lan K.K.G., Wittes J.T. Statistical monitoring of clinical trials: a unified approach 2006, Springer Science+Business Media, LLC, New York, New York.
17. Xiong X., Tan M., Boyett J. Sequential conditional probability ratio tests for normalized test statistics on information time. Biometrics 2003, 59:624-631.
18. Tan M. Conditional power in clinical trial monitoring. Wiley encyclopedia of clinical trials 2008, Wiley-Interscience. R. D'Agostino (Ed.).
19. Proschan M.A., Hunsberger S.A. Designed extension of studies based on conditional power. Biometrics 1995, 51(4):1315-1324.